Pavilion Publishing and Media Ltd
Blue Sky Offices Shoreham, 25 Cecil Pashley Way, Shoreham-by-Sea, West Sussex, BN43 5FF, UNITED KINGDOM
Tel: +44 (0)1273 434 943
Email: [email protected]
Conference report: EASL Congress 2023
The European Association for the Study of the Liver (EASL) is striving to become the ‘Home of Hepatology’ in a bid to bring together all who are involved in treating liver disease to cure and prevent it. This year, the EASL Congress took place in Vienna, Austria, where more than 6,000 delegates attended on site.
This conference report outlines some of key scientific highlights from the EASL Congress 2023 in Vienna, Austria. Resmetirom resolves NASH and improves fibrosis, early results suggest A phase III study has shown “promise” that resmetirom, an oral once daily treatment, may be able to treat patients with non-alcoholic steatohepatitis (NASH) and liver fibrosis. MAESTRO-NASH is a double-blind, randomised, placebo-controlled phase III trial evaluating the efficacy and safety of resmetirom in patients with biopsy confirmed NASH and fibrosis. The study is an ongoing 54-month trial involving 966 patients. Liver biopsies were read by two central pathologists using glass slides (primary analysis)
---------------------------
This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.